D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX)

Key Points

• D. Boral Capital reiterated a Buy rating on Turn Therapeutics with an $8.00 price target, implying about a 135.8% upside from the current share price of $3.39.
• Coverage is mixed—Weiss Ratings initiated with a Sell—leaving the stock with a consensus Hold rating based on one Buy and one Sell from analysts.
• Shares trade at $3.39 with a market cap of ~$99.9M and a negative P/E (‑48.23), a 52‑week range of $2.57–$26.50, and several institutional investors opened small positions in Q4.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock. D. Boral Capital's price objective would indicate a potential upside of 135.78% from the stock's current price.

Separately, Weiss Ratings began coverage on Turn Therapeutics in a report on Monday, January 5th. They set a "sell (e-)" rating on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $8.00.

Turn Therapeutics Price Performance

Shares of NASDAQ:TTRX traded down $0.03 during trading on Tuesday, reaching $3.39. The company had a trading volume of 16,237 shares, compared to its average volume of 31,020. The business's fifty day moving average is $3.88. The firm has a market cap of $99.89 million and a price-to-earnings ratio of -48.23. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50.

Institutional Trading of Turn Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TTRX. Hodges Capital Management Inc. acquired a new position in shares of Turn Therapeutics in the fourth quarter worth about $39,000. LPL Financial LLC purchased a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $51,000. Tamar Securities LLC purchased a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $59,000. Composition Wealth LLC acquired a new position in Turn Therapeutics in the 4th quarter worth approximately $63,000. Finally, Jane Street Group LLC purchased a new position in Turn Therapeutics during the 4th quarter worth approximately $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.